2024
Influence of patient characteristics on Helicobacter pylori eradication with Vonoprazan: A subgroup analysis of the pHalcon‐HP trial
Chey W, Mégraud F, Laine L, Smith N, Leifke E, Hunt B, Howden C. Influence of patient characteristics on Helicobacter pylori eradication with Vonoprazan: A subgroup analysis of the pHalcon‐HP trial. JGH Open 2024, 8: e70044. PMID: 39554983, PMCID: PMC11567116, DOI: 10.1002/jgh3.70044.Peer-Reviewed Original Research
2022
International multicenter study comparing demographics, therapy and outcomes in bleeding from Mallory Weiss tears and peptic ulcers
Tham JE, Lynch L, Laursen SB, Laine L, Dalton HR, Ngu J, Redondo-Cerezo E, Schultz M, Murray I, Michell N, Morris AJ, Nielsen MM, Stanley AJ. International multicenter study comparing demographics, therapy and outcomes in bleeding from Mallory Weiss tears and peptic ulcers. Endoscopy International Open 2022, 10: e653-e658. PMID: 35571482, PMCID: PMC9106442, DOI: 10.1055/a-1784-0655.Peer-Reviewed Original ResearchMallory-Weiss tearUpper gastrointestinal bleedingPeptic ulcer bleedingEndoscopic therapyEndoscopic stigmataEpinephrine injectionAcute upper gastrointestinal bleedingInternational multicenter studyPUB patientsGastrointestinal bleedingUlcer bleedingUncommon causeMulticenter studyPeptic ulcerPoor outcomeScope clipInternational cohortClean baseLower riskBaseline parametersPatientsTherapyBleedingCommon modalityMortality
2021
Gastrointestinal Injury Caused by Aspirin or Clopidogrel Monotherapy Versus Dual Antiplatelet Therapy ∗
Bittl JA, Laine L. Gastrointestinal Injury Caused by Aspirin or Clopidogrel Monotherapy Versus Dual Antiplatelet Therapy ∗. Journal Of The American College Of Cardiology 2021, 79: 129-131. PMID: 34752903, DOI: 10.1016/j.jacc.2021.10.027.Commentaries, Editorials and Letters
2015
The effects of proton pump inhibition on patient‐reported severity of dyspepsia when receiving dual anti‐platelet therapy with clopidogrel and low‐dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial
Vardi M, Cryer BL, Cohen M, Lanas A, Schnitzer TJ, Lapuerta P, Goldsmith MA, Laine L, Doros G, Liu Y, McIntosh AI, Cannon CP, Bhatt DL. The effects of proton pump inhibition on patient‐reported severity of dyspepsia when receiving dual anti‐platelet therapy with clopidogrel and low‐dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial. Alimentary Pharmacology & Therapeutics 2015, 42: 365-374. PMID: 26032114, PMCID: PMC4494867, DOI: 10.1111/apt.13260.Peer-Reviewed Original ResearchConceptsDual anti-platelet therapyAnti-platelet therapyGastrointestinal Event TrialLow-dose aspirinNonpain symptomsEvents trialPatient-reported outcome dataPercent of patientsPatient-reported symptomsPatient-reported outcomesPatient-reported severityOmeprazole groupProphylactic omeprazoleCardiovascular safetyGastrointestinal bleedingPain intensityClinical eventsOmeprazole useClinical significanceOutcome dataAssessment QuestionnaireClopidogrelDyspepsiaTherapyPatients
2010
Treatment of Acute Bleeding
Laine L, Abid S, Albillos A, Kamath P, Vinel J, García‐Pagán J. Treatment of Acute Bleeding. 2010, 101-118. DOI: 10.1002/9781444393989.ch10.Chapters
2008
Intragastric pH With Oral vs Intravenous Bolus Plus Infusion Proton-Pump Inhibitor Therapy in Patients With Bleeding Ulcers
Laine L, Shah A, Bemanian S. Intragastric pH With Oral vs Intravenous Bolus Plus Infusion Proton-Pump Inhibitor Therapy in Patients With Bleeding Ulcers. Gastroenterology 2008, 134: 1836-1841. PMID: 18423628, DOI: 10.1053/j.gastro.2008.03.006.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralDrug Administration ScheduleDuodenal UlcerDuodenoscopyFemaleGastric AcidGastric Acidity DeterminationGastroscopyHumansHydrogen-Ion ConcentrationInfusions, IntravenousMaleMiddle AgedPeptic Ulcer HemorrhageProton Pump InhibitorsStomach UlcerTime FactorsTreatment OutcomeConceptsProton pump inhibitor therapyOral PPIIntravenous PPIInhibitor therapyConfidence intervalsStudy periodFrequent oral dosingHigh-risk stigmataSimilar antisecretory effectIntravenous lansoprazoleOral lansoprazolePPI therapyAntisecretory effectWide confidence intervalsIntragastric pHIntravenous bolusBleeding ulcersOral dosingPatientsBaseline pHUlcersAbstractTextTherapyAIMSBolus
2006
Session 5: Treatment of the Acute Bleeding Episode
Laine L, Planas R, Nevens F, Bañares R, Patch D, Bosch J. Session 5: Treatment of the Acute Bleeding Episode. 2006, 217-242. DOI: 10.1002/9780470988831.ch9.Chapters
2005
Early Heartburn Relief With Proton Pump Inhibitors: A Systematic Review and Meta-analysis of Clinical Trials
McQuaid KR, Laine L. Early Heartburn Relief With Proton Pump Inhibitors: A Systematic Review and Meta-analysis of Clinical Trials. Clinical Gastroenterology And Hepatology 2005, 3: 553-563. PMID: 15952097, DOI: 10.1016/s1542-3565(05)00023-6.Peer-Reviewed Original ResearchConceptsHeartburn reliefPPI therapyDay 1Clinical trialsSystematic reviewDouble-dose therapyEfficacy of PPIDays of therapyProton pump inhibitorsShort-term treatmentFirst placeboPPI doseMost patientsPooled proportionSustained reliefSymptom reliefRandomized comparisonPump inhibitorsInclusion criteriaPatientsMeta-AnalysisTherapyAbstractTextFirst dayHeartburn
2003
Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs1 1The Institute for Effectiveness Research, LLC, is a subsidiary of Medco Health Solutions, Inc., a Merck Company.
Laine L, Wogen J, Yu H. Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs1 1The Institute for Effectiveness Research, LLC, is a subsidiary of Medco Health Solutions, Inc., a Merck Company. Gastroenterology 2003, 125: 389-395. PMID: 12891540, DOI: 10.1016/s0016-5085(03)00900-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnti-Inflammatory Agents, Non-SteroidalCohort StudiesCost-Benefit AnalysisCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsFemaleGastrointestinal DiseasesHealth ResourcesHumansIsoenzymesLongitudinal StudiesMaleMembrane ProteinsMiddle AgedProstaglandin-Endoperoxide SynthasesRetrospective StudiesConceptsChronic NSAID therapyCoxib therapyNSAID therapyChronic nonsteroidal anti-inflammatory drug (NSAID) therapyNonsteroidal anti-inflammatory drug therapyAnti-inflammatory drug therapyHealth care resource utilizationCOX-2-specific inhibitorsU.S. administrative claims databaseMedco Health SolutionsProportion of patientsAdministrative claims databaseGastrointestinal eventsNewer coxibsInitial prescriptionChronic useClaims databaseDrug therapyClinical trialsDrug costsNew NSAIDClinical practicePatientsTherapyAbstractTextGI healthcare resource use in 6009 patients switching from chronic NSAID to COX-2 specific inhibitor therapy and the effect of prior PPI use
Laine L, Von Allmen H, Henderson S. GI healthcare resource use in 6009 patients switching from chronic NSAID to COX-2 specific inhibitor therapy and the effect of prior PPI use. Gastroenterology 2003, 124: a108. DOI: 10.1016/s0016-5085(03)80531-0.Peer-Reviewed Original ResearchIs it time for quadruple therapy to be first line?
Laine L. Is it time for quadruple therapy to be first line? 2003, 347-351. DOI: 10.1007/978-94-017-1763-2_36.ChaptersProton pump inhibitorsTriple therapyEradication ratePylori infectionCombination of PPIBismuth-based triple therapyPooled eradication ratesH. pylori infectionHelicobacter pylori infectionQuadruple therapyEarly therapyCurrent therapiesPump inhibitorsSeparate medicationsTherapyFirst lineInfectionStudies2–4MedicationsHelicobacter pylori eradication does not benefit non-ulcer dyspepsia
Laine L. Helicobacter pylori eradication does not benefit non-ulcer dyspepsia. 2003, 275-281. DOI: 10.1007/978-94-017-1763-2_28.ChaptersNon-ulcer dyspepsiaH. pylori eradication therapyPylori eradication therapyEradication therapyPylori eradicationH. pylori eradication treatmentH. pylori eradicationHelicobacter pylori eradicationPylori eradication treatmentH. pylori treatmentPylori treatmentEradication treatmentTreatment successDyspepsiaHelicobacter pyloriAetiological agentSerious methodological flawsTrialsSmall benefitPotential roleSignificant differencesMethodological flawsTherapyEradicationTreatment
2002
Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial
Laine L, Dhir V. Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial. Alimentary Pharmacology & Therapeutics 2002, 16: 1143-1148. PMID: 12030957, DOI: 10.1046/j.1365-2036.2002.01267.x.Peer-Reviewed Original ResearchMeSH Keywords2-PyridinylmethylsulfinylbenzimidazolesAdultAmoxicillinAnti-Bacterial AgentsAnti-Ulcer AgentsBreath TestsClarithromycinDrug Therapy, CombinationDyspepsiaFemaleGastroesophageal RefluxHelicobacter InfectionsHumansLansoprazoleMaleMiddle AgedOmeprazolePenicillinsProspective StudiesQuality of LifeUreaConceptsGastro-oesophageal reflux diseaseQuality of lifeH. pylori therapyPylori therapyReflux diseaseH. pyloriSymptomatic gastro-oesophageal reflux diseaseHelicobacter pylori eradicationHelicobacter pylori therapyPopulation of patientsEnd of therapyUrea breath testReflux symptomsPylori eradicationTriple therapyProspective trialEndoscopic biopsyPrimary complaintProspective studyLife QuestionnaireBreath testPatientsTherapyMonthsSymptoms
2001
Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials.
Laine L, Schoenfeld P, Fennerty M. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Annals Of Internal Medicine 2001, 134: 361-9. PMID: 11242496, DOI: 10.7326/0003-4819-134-5-200103060-00008.Peer-Reviewed Original ResearchConceptsH. pylori eradication therapyNonulcer dyspepsiaPylori eradication therapyEradication therapyControl therapyOdds ratioH. pyloriHelicobacter pyloriDefinition of dyspepsiaDuplicate data extractionEnd of therapyH. pylori infectionAnalysis of trialsPylori infectionCombination therapyMethodologic qualityTreatment successDyspepsiaPersistent infectionReference listsTherapyPatientsStudy designPrimary investigatorPyloriSession 6 ‒ Treatment of the Acute Bleeding Episode
Laine L, Burroughs A, Silvain C, Vinel J, Bosch J. Session 6 ‒ Treatment of the Acute Bleeding Episode. 2001, 134-169. DOI: 10.1002/9780470760154.ch10.Chapters
2000
Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials
Laine L, Fennerty M, Osato M, Sugg J, Suchower L, Probst P, Levine J. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. The American Journal Of Gastroenterology 2000, 95: ajg20001583. PMID: 11151867, DOI: 10.1111/j.1572-0241.2000.03349.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmoxicillinClarithromycinDouble-Blind MethodDrug Administration ScheduleDrug Resistance, MicrobialDrug Therapy, CombinationDuodenal UlcerEsomeprazoleFemaleHelicobacter InfectionsHelicobacter pyloriHumansMaleMiddle AgedPenicillin ResistancePenicillinsProspective StudiesProtein Synthesis InhibitorsProton Pump InhibitorsConceptsEradication rateClarithromycin resistanceDaily esomeprazoleTriple therapyDuodenal ulcerProton pump inhibitor-based triple therapyTen-day triple therapyHelicobacter pylori eradication therapyEmergent resistanceH. pylori-positive patientsInhibitor-based triple therapyDouble-blind trialTreat eradication ratesCompletion of therapyPylori eradication therapyPylori-positive patientsSeparate randomized trialsAntibiotic resistanceDaily amoxicillinUS multicenterEradication therapyRandomized trialsHelicobacter pyloriTherapyEsomeprazoleH. pylori therapy is not effective for treatment of non-ulcer dyspepsia: Meta-analysis of randomized controlled trials
Laine L, Schoenfeld P, Fennerty M. H. pylori therapy is not effective for treatment of non-ulcer dyspepsia: Meta-analysis of randomized controlled trials. Gastroenterology 2000, 118: a440. DOI: 10.1016/s0016-5085(00)83874-3.Peer-Reviewed Original Research
1999
Once-daily therapy for H. pylori infection: a randomized comparison of four regimens
Laine L, Estrada R, Trujillo M, Cheybani K, Yeramian P, Smith S, Neil G. Once-daily therapy for H. pylori infection: a randomized comparison of four regimens. The American Journal Of Gastroenterology 1999, 94: 962. PMID: 10201465, DOI: 10.1111/j.1572-0241.1999.995_r.x.Peer-Reviewed Original ResearchConceptsH. pylori infectionEradication ratePylori infectionExtended-release formulationDaily therapyBreath testDaily triple therapyHigh-dose omeprazoleTreat eradication ratesCompletion of therapyHelicobacter pylori infectionRepeat breath testStudy medicationTriple therapyEndoscopic biopsyRandomized comparisonLack of complianceTherapyPilot studyInfectionFurther studiesClarithromycinOmamDaysSubjects
1998
Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori.
Laine L, Estrada R, Trujillo M, Knigge K, Fennerty MB. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Annals Of Internal Medicine 1998, 129: 547-50. PMID: 9758575, DOI: 10.7326/0003-4819-129-7-199810010-00007.Peer-Reviewed Original ResearchConceptsUrea breath testProton pump inhibitor therapyBreath test resultsProton pump inhibitorsBreath testInhibitor therapyH. pyloriDiagnostic testingCompletion of therapyProportion of patientsNegative breath test resultH. pylori infectionUrea breath test resultsLansoprazole therapyFalse-negative resultsGastroenterology clinicPylori infectionPatientsHelicobacter pyloriTherapyDuration of conversionPyloriPositive resultsLansoprazoleDaysTwice-daily 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for H. Pylori eradication in duodenal ulcer disease: Results of 3 multicenter, double-blind, U.S. Trials
Laine L, Suchower L, Connors A, Frantz J, Neil G. Twice-daily 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for H. Pylori eradication in duodenal ulcer disease: Results of 3 multicenter, double-blind, U.S. Trials. Gastroenterology 1998, 114: a193. DOI: 10.1016/s0016-5085(98)80787-7.Peer-Reviewed Original Research